About This HOMA-IR Calculator
This HOMA-IR Calculator is a clinical tool that computes the Homeostatic Model Assessment for Insulin Resistance (HOMA-IR). It is widely used in both clinical practice and research to quantify insulin resistance from a single, fasting blood sample. By entering a patient’s fasting glucose and fasting insulin levels, this tool provides an index score that helps clinicians assess metabolic health, screen for individuals at risk of developing type 2 diabetes, and monitor response to lifestyle or therapeutic interventions aimed at improving insulin sensitivity. Current EASL-EASD-EASO guidance also notes that HOMA-IR may be used to document insulin resistance or metabolic dysfunction in people with suspected MASLD who do not have type 2 diabetes.
The Formula Explained
The HOMA-IR formula models the relationship between insulin and glucose in a fasting state, reflecting the balance between hepatic glucose output and beta-cell function. The denominator is a constant used to normalize the result to a value of approximately 1 for a healthy, insulin-sensitive individual (using the original assay calibration). HOMA-IR correlates well with the gold-standard hyperinsulinemic-euglycemic clamp, supporting its use as a practical surrogate measure of insulin resistance.
$$ \text{HOMA-IR} = \frac{\text{Fasting Insulin (μU/mL)} \times \text{Fasting Glucose (mg/dL)}}{405} $$
$$ \text{HOMA-IR} = \frac{\text{Fasting Insulin (μU/mL)} \times \text{Fasting Glucose (mmol/L)}}{22.5} $$
Clinical Interpretation & Limitations
The HOMA-IR score is a continuous variable, but general cut-offs are commonly used to stratify risk. The ranges below are general reference points only — HOMA-IR has no single universal threshold. Because insulin immunoassays are not standardized and reference values differ by population, sex, and ethnicity, the cut-off that best identifies insulin resistance varies between studies and laboratories. In one large general-population study, for example, the optimal cut-off anchored to metabolic-syndrome risk was near 2.0, whereas the 90th-percentile value was roughly 3.5. Always interpret the score against your local laboratory’s reference values.
- HOMA-IR < 1.0: Suggests optimal insulin sensitivity.
- HOMA-IR 1.0 – 1.9: Generally considered a normal range.
- HOMA-IR > 1.9: Suggests early insulin resistance.
- HOMA-IR > 2.9: Suggests significant insulin resistance.
Limitations
This HOMA-IR Calculator provides an estimate, not a direct measurement of insulin resistance (like the hyperinsulinemic-euglycemic clamp). Because insulin assays are not harmonized across laboratories, absolute HOMA-IR values are not directly comparable between different labs or assays. Accuracy also depends on a true fasting sample. The score is less reliable in patients with very high glucose levels or those with compromised beta-cell function (e.g., established type 1 diabetes or late-stage type 2 diabetes), and it has not been validated for routine use in pregnancy.
Frequently Asked Questions (FAQ)
1. What is insulin resistance?
Insulin resistance is a physiological condition where cells in the body (especially muscle, fat, and liver cells) do not respond effectively to the hormone insulin. This means the pancreas must produce more insulin to help glucose enter cells. It is a key underlying factor in the development of metabolic syndrome and type 2 diabetes.
2. Why is a fasting blood sample required for the HOMA-IR calculator?
The “Homeostatic Model” is based on the steady-state balance between the liver’s glucose production and the pancreas’s insulin secretion in a resting, fasted state. After eating, both glucose and insulin levels rise dramatically, and this dynamic state does not reflect the body’s baseline insulin sensitivity.
3. Is HOMA-IR a diagnostic test for diabetes?
No. The diagnosis of diabetes is made on glucose criteria (fasting plasma glucose, HbA1c, or an oral glucose tolerance test) per the American Diabetes Association Standards of Care. The HOMA-IR Calculator assesses the underlying pathophysiology of insulin resistance, which is a risk factor for diabetes, but it is not itself a diagnostic criterion.
4. Is there a single universal HOMA-IR cut-off?
No. HOMA-IR has no universal threshold. Because insulin immunoassays are not standardized and reference values differ by population, sex, and ethnicity, cut-offs vary between studies and laboratories. For example, one large general-population study derived an insulin-resistance cut-off near 2.0 when anchored to metabolic-syndrome risk, versus roughly 3.5 at the 90th percentile. The ranges shown here are general reference points; interpret them against local laboratory values.
5. How does HOMA-IR compare to HbA1c?
They measure different things. HbA1c reflects your average blood glucose control over the past 2-3 months. HOMA-IR provides a snapshot of your current insulin sensitivity in a fasting state. A person could have a normal HbA1c but a high HOMA-IR, indicating that their body is successfully controlling blood sugar but only by producing an excessive amount of insulin (a state of compensated insulin resistance).
Related Calculators
📖 Sources:
- Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985 Jul;28(7):412-9.
- Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care. 2004 Jun;27(6):1487-95.
- Bonora E, Targher G, Alberiche M, et al. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity. Diabetes Care. 2000 Jan;23(1):57-63.
- Gayoso-Diz P, Otero-González A, Rodriguez-Alvarez MX, Gude F, García F, De Francisco A, Quintela AG. Insulin resistance (HOMA-IR) cut-off values and the metabolic syndrome in a general adult population: effect of gender and age. BMC Endocr Disord. 2013;13:47.
- European Association for the Study of the Liver (EASL), EASD, EASO. EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol. 2024 Sep;81(3):492-542.
⚠️ Disclaimer:
This tool is for informational and educational purposes only and is not a substitute for professional clinical judgment. All treatment decisions must be made by a qualified healthcare professional considering the individual patient’s full clinical context.
